industry · news · neuroscience · ipsc
Hopstem secures first Series C close for iPSC-derived neural cell therapy
Hopstem says the first close of its Series C will support clinical development and commercial manufacturing of its iPSC-derived forebrain neural progenitor programme.
Hopstem, Series C, iPSC, neural progenitors, stroke, cell therapy, regenerative medicine
Hopstem Biotechnology has announced the first close of a Series C financing round to advance its induced pluripotent stem cell-derived forebrain neural-cell programme. The company did not disclose the amount raised.
The round included Tasly Capital, Haibang Investment and Guangzhou Health Industry Investment, with existing investor Longmen Capital also participating. Hopstem says the proceeds will support clinical development and commercial-scale manufacturing.
The technological angle
Hopstem's lead product, hNPC01, is an injectable population of forebrain neural progenitor cells derived from iPSCs. The company is developing the candidate across neurological injuries, including chronic ischaemic stroke, haemorrhagic stroke and traumatic brain injury.
The platform challenge is not only producing the right neural lineage. A viable therapy requires a controlled, stable cell product that can be manufactured at scale, stored, delivered and compared consistently across clinical sites. Directing new capital toward manufacturing therefore matters alongside the clinical programme.
Hopstem reports that hNPC01 has received US regenerative medicine advanced therapy and Fast Track designations, and that additional investigational new drug applications have been cleared for haemorrhagic stroke and traumatic brain injury.
Why it matters
The financing reflects continued investor interest in iPSC technology beyond disease models and screening. A renewable pluripotent starting material could support standardized neural-cell production, but neurological cell replacement remains a demanding test of identity, integration, safety and durable function.
What to watch
The announcement is company-supplied and does not disclose the round size. The key evidence will come from peer-reviewed or fully reported clinical data, including safety, functional outcomes and durability, as well as evidence that manufacturing remains consistent as the programme expands across indications.
This HCMX news brief is an independent summary of a company press release published on 10 August 2026.
References
Hopstem Biotechnology. Hopstem announces the first closing of Series C financing to accelerate the development of iPSC-derived forebrain neural cell therapy. 10 August 2026. https://www.biospace.com/press-releases/hopstem-announces-the-first-closing-of-series-c-financing-to-accelerate-the-development-of-ipsc-derived-forebrain-neural-cell-therapy